Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMBPN4K)

Drug Name
CAR-T cells targeting MucI Drug Info
Indication
Disease Entry ICD 11 Status REF
Lung cancer 2C25.0 Phase 1/2 [1]
Glioblastoma multiforme 2A00.0 Phase 1 [2]
Pancreatic cancer 2C10 Phase 1 [3]
Cross-matching ID
TTD Drug ID
DMBPN4K

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Mucin-1 (MUC1) TTBHFYQ MUC1_HUMAN CAR-T-Cell-Therapy [3]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Mucin-1 (MUC1) DTT MUC1 3.485 8.525 9.106 5.714
Mucin-1 (MUC1) DTT MUC1 3.485 8.525 9.106 5.714
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Lung cancer
ICD Disease Classification 2C25.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Mucin-1 (MUC1) DTT MUC1 4.59E-01 -0.07 -0.41
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT03356808) Antigen-specific T Cells Against Lung Cancer
2 ClinicalTrials.gov (NCT03170141) Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme
3 ClinicalTrials.gov (NCT03267173) Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer.